Author:
O’Regan Ruth M.,Gradishar William J.
Reference98 articles.
1. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:1451–1467.
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371–1388.
3. Schafer JI, Liu H, Tonetti DA, Jordan VC. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor (ER). Cancer Res 1999; 59:4308–4313.
4. Kangas L, Niemenen A.-L, Blanco G, Gronroos M, Kallio S, Karjalainen A, Perilla M, Soderwall M, Tiovola R. A new triphenylethylene compound Fc-1157a II antitumor effects. Cancer Chemo Pharm 1986; 17:109–113.
5. Warri AM, Huovinon RL, Laine AM, Mairtikainen PM, Harkonen PL. Apoptosis in toremifene growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 1993; 85:1412–1418.